Robert Balfour
Algemeen Directeur bij Promatix, Inc.
Profiel
Robert Balfour is currently the Chief Executive Officer at Promatix, Inc. and an Investment Director at Alsa Management Services Ltd.
He holds a doctorate degree from Imperial College London and an undergraduate degree from Southampton Business School.
Actieve functies van Robert Balfour
| Bedrijven | Functie | Begin |
|---|---|---|
Alsa Management Services Ltd
 Alsa Management Services Ltd Investment ManagersFinance Alsa Management Services Ltd (ALSA Ventures) is a venture capital firm founded in 2018. The firm is headquartered in London, United Kingdom. | Private Equity Investor | 01-07-2018 |
Promatix, Inc.
 Promatix, Inc. Data Processing ServicesTechnology Services Promatix, Inc. is based in London, UK. The British company takes a data-driven approach by utilizing a confluence of multi-omic datasets and proprietary algorithms. Promatix, Inc. is a company that was founded to accelerate the process of novel target and drug discovery for cancer patients. The company was founded in 2020, and Robert Balfour has been the CEO of the company since 2021. | Algemeen Directeur | 01-03-2021 |
Opleiding van Robert Balfour
| Imperial College London | Doctorate Degree |
| Southampton Business School | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
Alsa Management Services Ltd
Alsa Management Services Ltd Investment ManagersFinance Alsa Management Services Ltd (ALSA Ventures) is a venture capital firm founded in 2018. The firm is headquartered in London, United Kingdom. | Finance |
Promatix, Inc.
Promatix, Inc. Data Processing ServicesTechnology Services Promatix, Inc. is based in London, UK. The British company takes a data-driven approach by utilizing a confluence of multi-omic datasets and proprietary algorithms. Promatix, Inc. is a company that was founded to accelerate the process of novel target and drug discovery for cancer patients. The company was founded in 2020, and Robert Balfour has been the CEO of the company since 2021. | Technology Services |
